Top Markets
Coin of the day
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Rankning i aktier #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Aktiekurs
$0.5225
Senast synkroniserad: 2026-08-14
Marknadsvärde
$4.32M
Förändring (1 dag)
-1.60%
Förändring (1 år)
-63.72%
Land
IL
Handel Galmed Pharmaceuticals Ltd. (GLMD)

Kategori

Aktiekurshistorik för Galmed Pharmaceuticals Ltd. (GLMD)
Högsta slutkurs: $0.57 den 2026-08-01

Lägsta slutkurs: $2.34K den 2014-03-01
Aktiekurshistorik för Galmed Pharmaceuticals Ltd. från 2014 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) -9.47%
2025 -67.60%
2024 -35.91%
2023 -93.04%
2022 -82.49%
2021 -40.56%
2020 -40.27%
2019 -24.43%
2018 -7.34%
2017 144.28%
2016 -57.96%
2015 53.42%
2014 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE